{'fraction_non_alphanumeric': 0.052311435523114354, 'fraction_numerical': 0.025547445255474453, 'mean_word_length': 6.4818181818181815, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Initial clinical results with technetium‐99m‐labeled ll2 monoclonal antibody fragment in the radioimmunodetection of b‐cell lymphomas

Background. Various monoclonal antibodies (MoAb) labeled with Iodine‐131 or Indium‐111 (In‐111) have been investigated for radioimmunodetection of Hodgkin's and non‐Hodgkin's lymphomas. Successful radioimmuno‐therapy also has been reported. The purpose of this pilot study was to stage non‐Hodgkin's B‐cell lymphomas (NHL) using whole body scintigraphy with technetium‐99m (Tc‐99m)‐labeled murine monoclonal antibody LL2 (EPB‐2) Fab′ (Immunomedics, Morris Plains, NJ). Others have shown this MoAb to have specific binding to B‐cell lymphomas by flow cytometry and immunofluorescence. Initial clinical studies by others have demonstrated targeting of NHL with the Tc‐99m‐labeled LL2‐Fab′.